List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 100 studies with search of: Mesilato de nelfinavir OR Viracept[TREATMENT] AND HIV [CONDITION]
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Completed Safety Of VIRACEPT® 625mg Administered To HIV-Infected Women During Pregnancy
Condition: HIV Infection
Intervention: Drug: Nelfinavir mesylate, 625 mg
2 Suspended Effectiveness of a New Anti-HIV Drug (AG1549) Plus Viracept (Nelfinavir) Plus Combivir (Zidovudine/Lamivudine) in HIV-Infected Patients
Condition: HIV Infections
Interventions: Drug: Lamivudine/Zidovudine;   Drug: Capravirine;   Drug: Nelfinavir mesylate
3 Terminated A Comparison of Nelfinavir Plus Saquinavir Plus Delavirdine or 3TC/ZDV Versus Nelfinavir Plus 3TC/ZDV in HIV-Infected Patients
Condition: HIV Infections
Interventions: Drug: Lamivudine/Zidovudine;   Drug: Nelfinavir mesylate;   Drug: Saquinavir;   Drug: Delavirdine mesylate
4 Completed Viracept Expanded Access Program
Condition: HIV Infections
Intervention: Drug: Nelfinavir mesylate
5 Completed The Safety and Effectiveness of Nevirapine Plus Nelfinavir in HIV-1 Infected Patients Who Have Taken Stavudine
Condition: HIV Infections
Interventions: Drug: Nelfinavir mesylate;   Drug: Nevirapine;   Drug: Stavudine
6 Active, not recruiting A Study to Evaluate the Safety and Tolerance of Nelfinavir (NFV) Given With Zidovudine (ZDV) and Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants
Conditions: HIV Infections;   Pregnancy
Interventions: Drug: Nelfinavir mesylate;   Drug: Lamivudine;   Drug: Zidovudine
7 Completed A Study of Viracept in AIDS Patients With Mycobacterium Avium Complex Disease (MAC)
Conditions: Mycobacterium Avium-Intracellulare Infection;   HIV Infections
Intervention: Drug: Nelfinavir mesylate
8 Completed A Study on the Safety and Effectiveness of Twice-Daily Nelfinavir Plus Twice-Daily Indinavir Plus Efavirenz in HIV-Positive Patients Who Have Never Taken Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease Inhibitors
Condition: HIV Infections
Interventions: Drug: Indinavir sulfate;   Drug: Nelfinavir mesylate;   Drug: Efavirenz
9 Completed A Study of Viracept in HIV-Positive Women
Condition: HIV Infections
Intervention: Drug: Nelfinavir mesylate
10 Completed A Study of Capravirine Plus VIRACEPT Plus Two Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Patients Who Failed Previous Anti-HIV Treatments
Condition: HIV Infections
Interventions: Drug: Capravirine;   Drug: Nelfinavir mesylate
11 Completed A Pilot, Open-Label, Phase II, Randomized Study to Determine the Effects of Viracept on the Outcome of Cutaneous and Mucosal KS in AIDS Patients With CD4 <= 500 Cells/mm3
Conditions: Sarcoma, Kaposi;   HIV Infections
Intervention: Drug: Nelfinavir mesylate
12 Completed The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs
Conditions: HIV Infections;   HIV Seronegativity;   Lipodystrophy
Interventions: Drug: Pravastatin sodium;   Drug: Simvastatin;   Drug: Atorvastatin calcium;   Drug: Nelfinavir mesylate;   Drug: Efavirenz
13 Completed Combination Treatment Using Capravirine (AG1549), Nelfinavir, and Two Nucleoside Reverse Transcriptase Inhibitors in HIV Patients Who Failed Initial Combination Therapy
Condition: HIV Infections
Interventions: Drug: Capravirine;   Drug: Nelfinavir mesylate
14 Completed Phase I Study of Safety, Tolerability, and Pharmacokinetics of Viracept in HIV-1 Infected Children and Exposed Infants
Condition: HIV Infections
Intervention: Drug: Nelfinavir mesylate
15 Completed A Randomized, Double-Blind Study of MKC-442 Combined With Viracept in Patients Who Are Epivir + Retrovir Experienced and Are Protease Inhibitor- and Non-Nucleoside Reverse Transcriptase Inhibitor-Naive
Condition: HIV Infections
Interventions: Drug: Emivirine;   Drug: Nelfinavir mesylate
16 Active, not recruiting Treatment With Nelfinavir or Efavirenz of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs
Condition: HIV Infections
Interventions: Drug: Nelfinavir mesylate;   Drug: Efavirenz;   Drug: Lamivudine;   Drug: Keyhole-Limpet Hemocyanin;   Drug: Stavudine;   Drug: Zidovudine;   Drug: Didanosine
17 Active, not recruiting Comparison of GW433908 and Nelfinavir in HIV Patients Who Have Not Had Antiretroviral Therapy
Condition: HIV Infections
Interventions: Drug: Abacavir sulfate;   Drug: Nelfinavir mesylate;   Drug: Lamivudine;   Drug: GW433908
18 Active, not recruiting Comparison of GW433908/Ritonavir to Nelfinavir When Used With Abacavir and Lamivudine in Patients That Have Not Taken Antiretroviral Drugs
Condition: HIV Infections
Interventions: Drug: Ritonavir;   Drug: Abacavir sulfate;   Drug: Nelfinavir mesylate;   Drug: Lamivudine;   Drug: GW433908
19 Completed Optimizing Antiretroviral Therapy in HIV-Infected Children and Adolescents
Condition: HIV Infections
Interventions: Drug: Nelfinavir;   Drug: Lopinavir/ritonavir;   Drug: Ritonavir;   Drug: Amprenavir;   Drug: Indinavir;   Drug: Saquinavir;   Drug: Fosamprenavir;   Drug: Atazanavir;   Drug: Tipranavir;   Drug: Dose adjustment
20 Active, not recruiting A Randomized Trial of the Efficacy and Safety of a Strategy of Starting With Nelfinavir Versus Ritonavir Added to Background Antiretroviral (AR) Nucleoside Therapy in HIV-Infected Individuals With CD4+ Cell Counts Less Than or Equal to 200/mm3
Condition: HIV Infections
Interventions: Drug: Indinavir sulfate;   Drug: Ritonavir;   Drug: Nelfinavir mesylate

Previous Page Studies Shown (1-20) Next Page (21-40)
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services